Passage Bio logo

Passage BioNASDAQ: PASG

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

28 February 2020

Next earnings report:

04 March 2025

Last dividends:

N/A

Next dividends:

N/A
$32.10 M
-92%vs. 3y high
29%vs. sector
-vs. 3y high
-vs. sector
-64%vs. 3y high
24%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Wed, 20 Nov 2024 23:56:17 GMT
$0.52+$0.03(+6.21%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

PASG Latest News

Passage Bio to Present at Guggenheim Securities Healthcare Innovation Conference
globenewswire.com06 November 2024 Sentiment: POSITIVE

PHILADELPHIA , Nov. 06, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that Will Chou, M.D., president and chief executive officer, will present at Guggenheim Securities Healthcare Innovation Conference on Wednesday, November 13, 2024 at 2:30 p.m. ET.

Passage Bio Welcomes Tom Kassberg to Board of Directors
globenewswire.com10 September 2024 Sentiment: POSITIVE

PHILADELPHIA, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced the appointment of Tom Kassberg to the Board of Directors and his appointment to the Audit Committee. Mr. Kassberg is currently Chief Business Officer and Executive Vice President at Ultragenyx, a biopharmaceutical company committed to bringing novel therapies to patients for the treatment of serious rare and ultrarare genetic diseases.

Passage Bio Out-licenses Three Pediatric Gene Therapy Programs to GEMMA Biotherapeutics and Enters New Research Collaboration
globenewswire.com01 August 2024 Sentiment: POSITIVE

Granted exclusive, worldwide rights for the development and commercialization of PBGM01 for GM1 gangliosidosis, PBKR03 for Krabbe disease, and PBML04 for metachromatic leukodystrophy to GEMMA Biotherapeutics, a new company co-founded by Dr. James M. Wilson

Passage Bio (PASG) Loses -22.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
zacks.com18 June 2024 Sentiment: POSITIVE

The heavy selling pressure might have exhausted for Passage Bio (PASG) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

All You Need to Know About Passage Bio (PASG) Rating Upgrade to Buy
zacks.com16 May 2024 Sentiment: POSITIVE

Passage Bio (PASG) has been upgraded to a Zacks Rank #2 (Buy), indicating increasing confidence in the company's earnings potential. This could lead to a rise in the stock price in the short run.

Passage Bio, Inc. (PASG) Is Up 24.26% in One Week: What You Should Know
Zacks Investment Research07 March 2024 Sentiment: POSITIVE

Does Passage Bio, Inc. (PASG) have what it takes to be a top stock pick for momentum investors? Let's find out.

What type of business is Passage Bio?

Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

What sector is Passage Bio in?

Passage Bio is in the Healthcare sector

What industry is Passage Bio in?

Passage Bio is in the Biotechnology industry

What country is Passage Bio from?

Passage Bio is headquartered in United States

When did Passage Bio go public?

Passage Bio initial public offering (IPO) was on 28 February 2020

What is Passage Bio website?

https://www.passagebio.com

Is Passage Bio in the S&P 500?

No, Passage Bio is not included in the S&P 500 index

Is Passage Bio in the NASDAQ 100?

No, Passage Bio is not included in the NASDAQ 100 index

Is Passage Bio in the Dow Jones?

No, Passage Bio is not included in the Dow Jones index

When was Passage Bio the previous earnings report?

No data

When does Passage Bio earnings report?

The next expected earnings date for Passage Bio is 04 March 2025